Comparative trial of luteinizing hormone-releasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program

Abdalla, Hossam; Ahuja, Kamal; Leonard, T G A; Morris, Norman; Honour, John W.; Jacobs, Howard S.

doi:10.1016/s0015-0282(16)53343-3

Cited by 55 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus many oocyte containing follicles may develop in the sensitive polycystic ovary free from the adverse environment of high tonic LH levels. These oocytes appear to fertilise better than those obtained during cycles without pituitary desensitisation (Fleming et al 1988; Abdalla et al 1990), suggesting that it is indeed the abnormal hormonal milieu, rather than the polycystic ovary itself, that is the problem for women with the polycystic ovary syndrome.…”

Section: Treatmentmentioning

confidence: 94%

“…Six studies have examined the effect of pituitary desensitisation on miscarriage rates (Johnson & Pearce 1990; Abdalla et al 1990; Dor et al 1992; Saunders et al 1992; Balen et al 1993; Homburg et al 1993). Johnson and Pearce (1990) induced ovulation in women with PCOS who also had had recurrent miscarriage and found a significantly lower miscarriage rate in those who received buserelin for pituitary desensitisation together with FSH compared with those who received treatment with clomiphene citrate (2/20 vs 11/20).…”

Section: Treatmentmentioning

confidence: 99%

“…Johnson and Pearce (1990) induced ovulation in women with PCOS who also had had recurrent miscarriage and found a significantly lower miscarriage rate in those who received buserelin for pituitary desensitisation together with FSH compared with those who received treatment with clomiphene citrate (2/20 vs 11/20). In patients attending an assisted conception unit for IVF or gamete intrafallopian transfer (GIFT), treatment with buserelin and hMG was associated with a significantly lower rate of early pregnancy loss compared with the use of clomiphene and hMG (5/14 vs 3/33) (Abdalla et al 1990).…”

Section: Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Hypersecretion of luteinising hormone: a significant cause of infertility and miscarriage

Balen¹,

Tan²,

Jacobs³

1993

BJOG

Self Cite

155

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 94%

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Hypersecretion of luteinising hormone: a significant cause of infertility and miscarriage

Balen¹,

Tan²,

Jacobs³

1993

BJOG

Self Cite

155

View full text Add to dashboard Cite

“…90,93 The commonest is the long luteal phase protocol where GnRH agonists are started in the luteal phase of the cycle preceding the IVF cycle. 94,95 Efficacy in IVF/ICSI…”

Section: Multiple Pregnancymentioning

confidence: 99%

Recombinant follitropin alfa/lutropin alfa in fertility treatment

Gibreel

Bhattacharya²

2009

BTT

View full text Add to dashboard Cite

Recombinant human follicle stimulating hormone (rFSH) and luteinizing hormone (LH), also known as follitropin alpha and lutropin alpha, are manufactured by genetic engineering techniques which ensure high quality and batch to batch consistency. Follitropin alpha can be used for controlled ovarian hyperstimulation in assisted reproduction, ovulation induction for WHO group I and II anovulatory infertility and in men with hypogonadotrophic hypogonadism (HH) or idiopathic oligo-asthenospermia. Current evidence suggests superiority of urinary human menopausal gonadotropin (HMG) over follitropin alpha in controlled ovarian hyperstimulation for IVF in terms of live birth rate per couple. Addition of lutropin to follitropin alpha in an unselected IVF population does not appear to confer any benefit; however, it may have a role in ovulation induction in women with hypothalamic hypogonadism. Urinary HMG preparations (especially currently available highly purified preparations) are more cost effective than rFSH in terms of cost per ongoing pregnancy. However, women using rFSH injection pen devices have higher levels of satisfaction as compared to those using urinary HMG by means of conventional syringes.

show abstract

“…This suggests that it is indeed the abnormal hormonal milieu rather than the polycystic ovary itself. 125 With both long and short protocols, significantly more eggs are collected from woman with polycystic ovaries and the total dose of exogenous gonadotropins is the same for either regimen. 126…”

Section: Special Applications Pcosmentioning

confidence: 99%

GnRH Agonists, Antagonists, and Assisted Conception

Loenen

Huirne²,

Schats³

et al. 2002

Semin Reprod Med

View full text Add to dashboard Cite

Pituitary stimulation with pulsatile gonadotropin-releasing hormone (GnRH) induces both follicle-stimulating hormone and luteinizing hormone (LH). Blockade of pituitary gonadotropin secretion occurs upon desensitization when a continuous GnRH stimulus is provided by means an agonist or when the pituitary receptors are occupied with a competitive antagonist. The most common indication for blockade of pituitary gonadotropin secretion is with assisted reproduction treatment (ART) where it prevents premature luteinization. Originally by lack of clinically available GnRH antagonist, prolonged daily injection of agonist with its desensitizing effect was introduced for this purpose. Today, single- and multiple-dose injectable antagonists are also available to block the LH surge. This review provides an overview of the use of GnRH agonists and antagonists in assisted reproduction.

show abstract

Comparative trial of luteinizing hormone-releasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program

Cited by 55 publications

References 13 publications

Hypersecretion of luteinising hormone: a significant cause of infertility and miscarriage

Hypersecretion of luteinising hormone: a significant cause of infertility and miscarriage

Recombinant follitropin alfa/lutropin alfa in fertility treatment

GnRH Agonists, Antagonists, and Assisted Conception

Contact Info

Product

Resources

About